Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FFAR1 | O14842 | 16/20 | 0.55 |
| ▸ | PPARD | Q03181 | 8/20 | 0.55 |
| ▸ | PPARG | P37231 | 7/20 | 0.55 |
| ▸ | USP2 | O75604 | 1/20 | 0.44 |
| ▸ | GAA | P10253 | 1/20 | 0.44 |
| ▸ | PPARA | Q07869 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16609828 | 1.00 | FFAR1 (0.55) | FFAR1PPARDPPARGUSP2GAA | |
| SCHEMBL18512247 | 1.00 | FFAR1 (0.55) | FFAR1PPARDPPARGUSP2GAA | |
| SCHEMBL9275740 | 0.86 | FFAR1 (0.53) | FFAR1PPARDPPARGPPARA | |
| SCHEMBL435248 | 0.86 | FFAR1 (0.53) | FFAR1PPARDPPARGPPARA | |
| SCHEMBL9277990 | 0.86 | FFAR1 (0.53) | FFAR1PPARDPPARGPPARA | |
| SCHEMBL2691621 | 0.85 | PPARD (0.54) | FFAR1PPARDPPARGPPARA | |
| SCHEMBL13311839 | 0.85 | FFAR1 (0.46) | FFAR1PPARDPPARGPPARA | |
| SCHEMBL15292428 | 0.84 | FFAR1 (0.69) | FFAR1PPARDPPARGPPARA | |
| SCHEMBL15299338 | 0.84 | FFAR1 (0.69) | FFAR1PPARDPPARGPPARA | |
| SCHEMBL21979154 | 0.81 | PPARG (0.49) | FFAR1PPARDPPARGGAAPPARA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9783522-B2 | 2-amino-pyridine and 2-amino-pyrimidine derivatives and medicinal use thereof | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2017-10-10 | — | — | US | disclosed |
| US-20170044133-A1 | NOVEL 2-AMINO-PYRIDINE AND 2-AMINO-PYRIMIDINE DERIVATIVES AND MEDICINAL USE THEREOF | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2017-02-16 | — | — | US | disclosed |
| EP-2928886-B1 | NEW INDANYLOXYDIHYDROBENZOFURANYLACETIC ACIDS | BOEHRINGER INGELHEIM INT (DE) | 2016-11-02 | — | — | EP | disclosed |
| EP-2831053-B1 | NEW INDANYLOXYDIHYDROBENZOFURANYLACETIC ACID DERIVATIVES AND THEIR USE AS GPR40 RECEPTOR AGONISTS | BOEHRINGER INGELHEIM INT (DE) | 2016-06-22 | — | — | EP | disclosed |
| EP-2831064-B1 | NEW INDANYLOXYDIHYDROBENZOFURANYLACETIC ACID DERIVATIVES AND THEIR USE AS GPR40 RECEPTOR AGONISTS | BOEHRINGER INGELHEIM INT (DE) | 2016-02-17 | — | — | EP | disclosed |
| US-8952185-B2 | Production method of optically active dihydrobenzofuran derivative | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2015-02-10 | — | — | US | disclosed |
| WO-2013144097-A1 | NEW INDANYLOXYDIHYDROBENZOFURANYLACETIC ACID DERIVATIVES AND THEIR USE AS GPR40 RECEPTOR AGONISTS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2013-10-03 | — | — | WO | disclosed |
| WO-2013144098-A1 | NEW INDANYLOXYDIHYDROBENZOFURANYLACETIC ACID DERIVATIVES AND THEIR USE AS GPR40 RECEPTOR AGONISTS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2013-10-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170044133-A1 | NOVEL 2-AMINO-PYRIDINE AND 2-AMINO-PYRIMIDINE DERIVATIVES AND MEDICINAL USE THEREOF | ENPP2, ATXN2, ATXN2L | FFAR1 4612/4885PPARD 4139/4885PPARG 4069/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.